Limbic-Predominant Age-Related TDP-43 Encephalopathy and the Frontier of Mixed Dementias: A Comprehensive Clinical Analysis

Recent advancements in neurodegenerative research have shed light on complex cognitive impairments that frequently confound traditional diagnostic paradigms. On a recent installment of the GeriPal Podcast, hosts Eric Widera and Alex Smith sat down with prominent dementia researchers and clinicians from the University of Wisconsin—Dr. Nate Chin, a geriatrician and medical director of the Alzheimer’s Disease Research Center, and Dr. Sterling Johnson, a clinical neuropsychologist and principal investigator of the CLARiTI study. Their discussion centered on Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE), the prevalence of mixed dementias, and the urgent necessity for diagnostic precision as modern medicine enters an era of disease-modifying therapies.

The Landscape of Cognitive Impairment and the Emergence of LATE

For decades, clinical diagnoses of dementia and mild cognitive impairment (MCI) have heavily leaned toward Alzheimer’s disease as the default etiology for memory loss. However, neuropathological autopsies consistently reveal a more complicated reality: pure single-pathology neurodegenerative diseases are often the exception rather than the rule, particularly among older adults.

LATE, officially designated as a distinct clinical entity in 2019, represents a major paradigm shift in how researchers understand memory loss in the oldest old. Clinically, LATE mimics Alzheimer’s disease by primarily affecting the limbic system—specifically the hippocampus and the amygdala—resulting in pronounced short-term memory loss and a remarkably slow cognitive decline. Despite these striking clinical similarities, patients with LATE frequently test negative for amyloid plaques and tau tangles, the hallmark proteinopathies of Alzheimer’s disease.

Instead, LATE is driven by the mislocalization and aggregation of the TAR DNA-binding protein 43 (TDP-43). Normally functioning as a nuclear quality-control protein involved in RNA and DNA splicing, TDP-43 mislocates to the cytoplasm in affected neurons, forming clumps that disrupt cellular homeostasis. Because current clinical diagnostic criteria rely heavily on symptoms rather than in-vivo biomarkers for TDP-43, diagnosing LATE during a patient’s life remains challenging, typically requiring post-mortem examination or careful exclusion of alternative pathologies.

The Phenomenon of Mixed Dementias

The clinical discourse surrounding neurodegeneration is rapidly pivoting away from isolated disease models toward the broader concept of mixed dementias. As Dr. Johnson noted during the discussion, the brain is subjected to multiple overlapping insults as individuals age. The major proteinopathies driving cognitive decline include Alzheimer’s disease (amyloid and tau), Lewy body disease (alpha-synuclein), and TDP-43 disorders (encompassing frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and LATE), alongside cerebrovascular disease.

Epidemiological and neuropathological data indicate that these pathologies frequently co-occur. For individuals diagnosed with dementia in their late 70s or 80s, the probability of presenting with pure Alzheimer’s disease is less than 25 percent. Furthermore, autopsy studies show that 40 to 60 percent of brains exhibiting Alzheimer’s neuropathological changes also harbor co-occurring TDP-43 proteinopathy.

When multiple pathologies overlap, the rate of cognitive decline accelerates significantly. While LATE in isolation typically manifests as an indolent, slow-progressing memory impairment in individuals over the age of 80, its co-occurrence with Alzheimer’s disease or alpha-synuclein pathologies results in a more rapid and severe clinical trajectory.

Diagnostic Dilemmas and the Biomarker Revolution

The rapid development of accessible biomarkers—most notably the p-Tau 217 blood test for Alzheimer’s disease—has revolutionized clinical trials and specialty practice. Clinicians can now accurately detect Alzheimer’s proteinopathy in living patients with high precision. However, this technological advancement has created a dual-edged sword: the medical community risks hyper-focusing on proteinopathies that are easily diagnosed via blood or PET imaging while neglecting those, like TDP-43 and alpha-synuclein, that lack commercial in-vivo biomarkers.

This diagnostic blind spot complicates clinical trial design for disease-modifying therapies such as anti-amyloid monoclonal antibodies (e.g., lecanemab and donanemab). Clinical trials for these therapeutics historically enrolled carefully selected populations with minimal comorbid pathology. Yet, recent phase trials incorporating comprehensive copathology testing—such as cerebrospinal fluid seed amplification assays for alpha-synuclein—reveal that up to 30 percent of participants in purportedly "pure" Alzheimer’s cohorts harbor secondary proteinopathies. Experts suggest that the presence of these unmeasured mixed pathologies may partially explain why anti-amyloid treatments, while successful in clearing amyloid and slowing cognitive decline by 26 to 35 percent, do not halt disease progression entirely.

Clinical Implications and Patient Management

For practicing clinicians, recognizing LATE and mixed dementias fundamentally transforms the nature of patient counseling and disease management. When biomarker testing rules out Alzheimer’s disease in an older patient experiencing progressive memory loss, identifying probable LATE offers vital prognostic reassurance.

Because LATE progresses exceptionally slowly compared to typical Alzheimer’s disease, patients and their families can be counseled with a degree of optimism regarding life expectancy and trajectory. Although disease-modifying therapies do not yet exist for TDP-43 or alpha-synuclein, management strategies remain anchored in palliative care, non-pharmacological lifestyle interventions, cognitive structuring, and caregiver support. Nonspecific pharmacotherapies, such as cholinesterase inhibitors (e.g., donepezil) and memantine, continue to be utilized pragmatically to support quality of life and manage behavioral symptoms, regardless of the underlying proteinopathy.

The Future Landscape: Precision Medicine and Diversity in Research

Looking toward the next decade, the scientific community faces the challenge of developing reliable, non-invasive biomarkers for non-Alzheimer proteinopathies. Initiatives such as the CLARiTI study (Consortium for Clarity in ADRCs), which has enrolled nearly 1,000 diverse participants across multiple national Alzheimer’s Disease Research Centers (ADRCs), represent significant strides toward unraveling the complexities of mixed dementias.

Crucially, modern research consortia are prioritizing demographic and geographic diversity to ensure findings are generalizable across broader populations. With the National Alzheimer’s Coordinating Center (NACC) pooling data from tens of thousands of individuals from varied racial, ethnic, and socioeconomic backgrounds, the medical field is moving closer to an era of truly personalized neurodegenerative care.

The ultimate vision for the field over the next five to ten years involves multimodal diagnostic capabilities capable of detecting all underlying proteinopathies in the preclinical phase. By identifying these overlapping pathological processes early, future therapeutic interventions could utilize combination treatments tailored to an individual’s unique molecular profile. The ultimate goal, as highlighted by leading researchers, is to delay cognitive decline and prevent the debilitating end stages of dementia so that aging individuals ultimately succumb to non-neurological causes, transforming neurodegenerative diseases from inevitable tragedies into manageable conditions.